NCT05789537

A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors

A Global, Open-label Study to Investigate the Efficacy and Safety of SerpinPC in Subjects with Hemophilia B with Inhibitors

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: ApcinteX Ltd · Industry
• Sex: Male
• Age: 12 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the efficacy, safety, tolerability and pharmacokinetic (PK) profile of prophylactic SerpinPC in participants with Hemophilia B with inhibitors, as part of the SerpinPC registrational program.

Conditions

• Hemophilia B with Inhibitor
• Hemophilia B

Interventions

Type	Name	Description
DRUG	SerpinPC	Administered as SC injection.

Timeline

• Start date: 2023-07-28
• Primary completion: 2024-11-14
• Completion: 2025-02-24
• First posted: 2023-03-29
• Last updated: 2025-03-11

Locations

20 sites across 11 countries: United States, Armenia, Australia, France, Germany, India, Italy, Spain, Taiwan, Turkey (Türkiye), United Kingdom

Regulatory

• FDA-regulated drug study